Merit Medical Systems (NASDAQ:MMSI) Raised to Strong-Buy at Wall Street Zen

Merit Medical Systems (NASDAQ:MMSI) was upgraded by Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued on Saturday.

Several other equities research analysts have also issued reports on the company. Wells Fargo & Company lowered Merit Medical Systems from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $95.00 to $78.00 in a report on Thursday, February 26th. Piper Sandler cut their price objective on shares of Merit Medical Systems from $113.00 to $106.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 18th. Barrington Research lifted their target price on shares of Merit Medical Systems from $106.00 to $109.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Needham & Company LLC decreased their target price on shares of Merit Medical Systems from $108.00 to $101.00 and set a “buy” rating for the company in a research report on Wednesday, February 25th. Finally, BTIG Research began coverage on shares of Merit Medical Systems in a research report on Friday, February 6th. They issued a “buy” rating and a $107.00 target price for the company. Seven research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $101.25.

Merit Medical Systems Price Performance

Shares of NASDAQ:MMSI opened at $68.73 on Friday. The company has a current ratio of 4.34, a quick ratio of 2.95 and a debt-to-equity ratio of 0.46. Merit Medical Systems has a 1 year low of $66.34 and a 1 year high of $107.27. The business has a fifty day simple moving average of $76.85 and a 200 day simple moving average of $82.28. The firm has a market cap of $4.08 billion, a price-to-earnings ratio of 32.42, a P/E/G ratio of 2.00 and a beta of 0.62.

Merit Medical Systems (NASDAQ:MMSI) last released its quarterly earnings data on Tuesday, February 24th. The medical instruments supplier reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.96 by $0.08. Merit Medical Systems had a return on equity of 13.82% and a net margin of 8.48%.The firm had revenue of $393.94 million during the quarter, compared to analysts’ expectations of $390.77 million. During the same quarter last year, the firm earned $0.93 earnings per share. The business’s revenue for the quarter was up 10.9% on a year-over-year basis. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. As a group, sell-side analysts predict that Merit Medical Systems will post 3.37 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Los Angeles Capital Management LLC bought a new position in shares of Merit Medical Systems in the 4th quarter valued at approximately $25,000. Maseco LLP acquired a new position in Merit Medical Systems during the fourth quarter valued at approximately $26,000. Salomon & Ludwin LLC bought a new position in shares of Merit Medical Systems in the third quarter valued at approximately $37,000. Torren Management LLC bought a new position in shares of Merit Medical Systems in the fourth quarter valued at approximately $38,000. Finally, Covestor Ltd lifted its stake in shares of Merit Medical Systems by 252.6% in the fourth quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock worth $41,000 after buying an additional 336 shares during the last quarter. 99.66% of the stock is owned by institutional investors.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.